Compounded TB-500
TB-500 was removed from the FDA's Category 2 bulk-substances list on April 15, 2026. The Pharmacy Compounding Advisory Committee (PCAC) reviewed compounding eligibility on 2026-07-23. Until that ruling is published and applied, 503A pharmacies cannot lawfully compound TB-500 from bulk substances.
Pepticker primarily tracks research-use peptide pricing across registered research-chemical vendors. The 503A compounding-pharmacy channel is a different regulatory universe — it requires an individualized prescription, a licensed pharmacist, and a substance that is either FDA-approved or on the 503A bulk-substances list. The April 15, 2026 Category 2 removal disrupted that pipeline for the seven peptides on this directory, and PCAC is the body that decides whether it gets restored.
This page exists so that within 72 hours of a favorable PCAC ruling, a verified directory of US 503A pharmacies that actually compound TB-500 can be published here. We do not pre-list pharmacies; the directory only goes live with verified, currently-active entries.
TB-500 is a synthetic fragment of thymosin beta-4 studied in animal models for soft-tissue repair, actin-cytoskeleton modulation, and inflammation control. Equine veterinary literature is the largest single body of in-vivo data; human clinical evidence is preliminary.
Live research-use vendor pricing for TB-500 is tracked on the standard Pepticker PDP: TB-500 price comparison.
TB-500 was removed from FDA Category 2 on April 15, 2026, pending PCAC review on July 23-24, 2026. 503A pharmacies cannot compound it from bulk until that ruling. Research-use purchase from peptide vendors remains the only current legal channel — see the Pepticker TB-500 PDP for tracked $/mg.
Favorable ruling pathway
A favorable PCAC vote returns TB-500 to the 503A bulk-substances pipeline. State-licensed 503A compounding pharmacies that hold the appropriate non-sterile (or sterile-injectable, depending on dosage form) facility licensing would once again be able to dispense patient-specific prescriptions written by a licensed prescriber. In that scenario, this page will publish a verified directory of pharmacies that actually carry compounded TB-500, including state of license and any telehealth-clinic relationships. Listings will be sourced from state board of pharmacy records and direct verification — not vendor self-reporting.
Unfavorable ruling pathway
An unfavorable PCAC vote keeps TB-500 off the 503A bulk-substances list. In that scenario the only legal channels in the United States remain (a) research-only purchase from registered research-chemical vendors and (b) any FDA-approved finished drug that happens to contain TB-500 as an active ingredient (none currently exist for the peptides in this directory). This page would shift to a regulatory-history explainer rather than a pharmacy directory, and the research-use price comparison at /peptides/tb-500 would remain the canonical Pepticker resource.
503A pharmacies compounding TB-500
No verified pharmacy listings yet. This section will populate within 72 hours of a favorable PCAC vote outcome. We do not publish speculative or unverified pharmacy directories — see Pepticker methodology for sourcing standards.
Pharmacy directory is informational only. Not medical, legal, or prescribing advice. Directory eligibility is sourced from state boards of pharmacy and direct verification — see /methodology for sourcing.
More on TB-500 & PCAC-track peptides
- TB-500 price comparison— Live $/mg across tracked research vendors.